↓ Skip to main content

Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer

Overview of attention for article published in BMC Complementary and Alternative Medicine, September 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Readers on

mendeley
11 Mendeley
Title
Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer
Published in
BMC Complementary and Alternative Medicine, September 2017
DOI 10.1186/s12906-017-1971-1
Pubmed ID
Authors

Roman Huber, Dietrich Schlodder, Carola Effertz, Sabine Rieger, Wilfried Tröger

Abstract

Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on Intravenous application are limited. An aqueous extract from pine-mistletoe was used to investigate maximum tolerable dose (MTD) and safety of intravenous application. It was infused once weekly for 3 weeks in patients with advanced cancer. Any type of cancer was included; relevant exclusion criteria were concurrent chemo- or radiation therapy. The classical phase I 3 + 3 dose escalation scheme was followed. Predefined dose groups were 200, 400, 700, 1200 and 2000 mg. Maximum planned dose was 2000 mg. With the MTD three more patients should be treated for 9 weeks in order to evaluate intermediate term tolerability. Weekly during the treatment and 1 week later tolerability, clinical status, safety laboratory parameters and adverse events were documented. Twenty-one patients (3 in the dose groups 200, 400, 700 and 1200 mg, respectively, 9 in the dose group 2000 mg) were included. MTD was not reached. Because one dose-limiting toxicity (DLT), an allergic reaction, occurred during infusion of 2000 mg, three more patients had to be included in this dose group and tolerated it, as well as the three patients who received 2000 mg for 9 weeks. Occasionally in the dose group 2000 mg mild to moderate fever occurred. Weekly infusions of 2000 mg of the pine-mistletoe extract were tolerated and can be used in further studies but had a risk for allergic reactions and fever. German Clinical Trials Register (Trial registration number DRKS00005028).

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 9%
Unknown 10 91%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 27%
Unspecified 2 18%
Student > Bachelor 2 18%
Lecturer 1 9%
Other 1 9%
Other 2 18%
Readers by discipline Count As %
Medicine and Dentistry 5 45%
Unspecified 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 2 18%
Nursing and Health Professions 1 9%
Environmental Science 1 9%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2017.
All research outputs
#9,447,125
of 11,823,343 outputs
Outputs from BMC Complementary and Alternative Medicine
#1,676
of 2,431 outputs
Outputs of similar age
#196,397
of 267,804 outputs
Outputs of similar age from BMC Complementary and Alternative Medicine
#12
of 15 outputs
Altmetric has tracked 11,823,343 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,431 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,804 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.